- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02689830
Prostate Embolization for Acute Urinary Retention Study (PARIS1)
Prostate Embolization for Acute Urinary Retention Study (PARIS 1): An Open-label Prospective Study
Study Overview
Detailed Description
This is an open-label prospective, multicenter (centralized procedure), single arm, sequentially enrolling study. Twenty subjects will be enrolled in the study.
Patient will be referred by the attending urologists after failure of the currently recommended approach of Trial WithOut Catheter (TWOC) and alpha-adrenergic receptor (AR) blockers.
It is expected that all AUR cases referred to the local urological clinic will be considered for inclusion in the trial. A trial log book will be completed by the referring local urologist in order to obtain preliminary data on the applicability of the trial to all AUR comers in the institution. This log book will be limited to a very simple questionnaire to ensure high rate of completion by the attending resident/fellow (Patients age, size of prostate, previous Benign Prostate Hypertrophy symptoms, renal function). It will be used in order to assess the external validity of this first phase trial and will be a help to design the potential next step trial.
When a patient will present with AUR in the corresponding urological clinic, the PI and Clinical research coordinator will be informed by a short text message, fax or e-mail in order to prepare the following process.
Patient will be informed by the urologist of the ongoing research project. In summary, this will consist in informing the patient that the first step is TWOC and in case of failure of TWOC several options are offered including PAE in the trial setting. Inclusion of the patient will considered only in case of failure of TWOC.
If the patient is willing to participate, patient will be seen in clinic by the Principal Investigator or co-investigator in order to inform him of the protocol and obtain signed informed consent.
PAE will be scheduled upon the first contact to make sure that PAE is performed in a short delay following failure of TWOC. The goal is to perform PAE in the week following recatheterization. For practical reasons this delay might be extended and will be recorded in the Case Report Form.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75015
- Hopital Europeen Georges Pompidou
-
Paris, France, 75014
- Hopital Cochin
-
Paris, France, 75010
- Hôpital Saint-Louis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- AUR Patients presenting with a first episode of AUR related to BPH (no matter if previously known or not) AND
- Failure of at least one TWOC AND
- Prostate size > or = 50 ml (ultrasound measurement)
Exclusion Criteria:
- Known hypocontractile bladder
- AUR related to other causes (Acute prostatitis or documented Prostate cancer)
- Severe iodine allergy
- Known prostate cancer
- Known ongoing acute or chronic prostatitis
- On-going acute pyelonephritis or septicemia from urinary origin
- Patient refusing PAE
- Severe renal failure (creatinine Clearance < 20 ml/min (MDRD)
- Contra-indication to AR blockers (postural hypotension micturition syncope)
- Contra-indication to anticoagulants
- Patient catheterized with a suspubian catheter
- Patient <18
- Patients who are prisoners
- Patients who are mentally incapacitated
- Patients participating in an investigational study involving the peripheral vasculature
- Patients unable or unwilling to provide written informed consent
- Patients ineligible for pelvic angiography and embolization including severe atheromatous condition or any anatomical condition
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bead Block microspheres
Prostate embolization
|
Prostate embolization
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Procedure success
Time Frame: 6 months after PAE
|
percentage of patients free of Foley and/or any prostate surgery
|
6 months after PAE
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of procedure related or contributed complications
Time Frame: 1 week after PAE
|
1 week after PAE
|
|
Percentage of immediate technical success of embolization
Time Frame: 5 minutes after the beginning of the procedure
|
Percentage of bilateral embolization
|
5 minutes after the beginning of the procedure
|
Cumulative number of per-procedure angiographic and clinical complications
Time Frame: 24 hours after PAE
|
according to the Society of Interventional Radiology and Dindo classifications
|
24 hours after PAE
|
Immediate technical success of embolization
Time Frame: 5 minutes after the beginning of the procedure
|
percentage of unilateral versus percentage of bilateral embolization
|
5 minutes after the beginning of the procedure
|
Comparison of International Prostate Symptom Score
Time Frame: between pre-PAE and 3 months post-PAE
|
between pre-PAE and 3 months post-PAE
|
|
Comparison of International Index of Erectile Function
Time Frame: between pre-PAE and 3 months post-PAE
|
between pre-PAE and 3 months post-PAE
|
|
Comparison of Quality of Life Questionnaire
Time Frame: between pre-PAE and 3 months post-PAE
|
between pre-PAE and 3 months post-PAE
|
|
Comparison of International Prostate Symptom Score
Time Frame: between pre-PAE and 6 months post-PAE
|
between pre-PAE and 6 months post-PAE
|
|
Comparison of International Index of Erectile Function
Time Frame: between pre-PAE and 6 months post-PAE
|
between pre-PAE and 6 months post-PAE
|
|
Comparison of Quality of Life Questionnaire
Time Frame: between pre-PAE and 6 months post-PAE
|
between pre-PAE and 6 months post-PAE
|
|
Number of re-catheterization
Time Frame: 6 months after PAE
|
6 months after PAE
|
|
Time of re-catheterization
Time Frame: 6 months after PAE
|
6 months after PAE
|
|
Time until TransUrethral Resection of the Prostate or open surgery
Time Frame: 6 months
|
6 months
|
|
Cumulative number of days with bladder catheter
Time Frame: between PAE and 6 months post-PAE
|
between PAE and 6 months post-PAE
|
|
Number of patients free of bladder catheter
Time Frame: between PAE and 6 months post-PAE
|
between PAE and 6 months post-PAE
|
|
Number of cumulated hospitalization days
Time Frame: between initial AUR and 6 months post-PAE
|
between initial AUR and 6 months post-PAE
|
|
Number of cumulated hospitalization days
Time Frame: between PAE and 6 months post-PAE
|
between PAE and 6 months post-PAE
|
|
Total number of consultations
Time Frame: between PAE and 6 months post-PAE
|
consultations with interventional radiologist and/or urologist
|
between PAE and 6 months post-PAE
|
Prostate volume
Time Frame: 6 months
|
Measured with MRI or ultrasound
|
6 months
|
Comparison of the number of Benign Prostate Hypertrophy medication
Time Frame: before and 3 months after PAE
|
before and 3 months after PAE
|
|
Comparison of the number of Benign Prostate Hypertrophy medication
Time Frame: before and 6 months after PAE
|
before and 6 months after PAE
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marc SAPOVAL, HEGP, Paris
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SA-112043
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Hypertrophy, Benign
-
Chong Kun Dang PharmaceuticalCompletedBenign Prostatic Hypertrophy (BPH)Korea, Republic of
-
Indiana Kidney Stone InstituteRichard Wolf Medical Instruments Corporation (RWMIC)CompletedBenign Prostatic Hypertrophy Requiring Surgical InterventionUnited States
-
San Carlo di Nancy HospitalElesta S.R.L.CompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy | Benign Prostatic Hypertrophy With Outflow Obstruction | Prostate HyperplasiaItaly
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Not yet recruitingLower Urinary Tract Symptoms | Benign Prostate Hyperplasia | Benign Prostatic Hypertrophy With Outflow Obstruction
-
Boston Scientific CorporationCompletedProstatic Hyperplasia | Benign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy | Prostatic Hypertrophy, Benign | Adenoma, Prostatic | Prostatic Adenoma | RezumDominican Republic, Czechia, Sweden
-
Boston Scientific CorporationCompletedBenign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy | Prostatic Hypertrophy, Benign | Adenoma, Prostatic | Prostatic Adenoma | RezumDominican Republic
-
IMBiotechnologies Ltd.CompletedBenign Prostatic Hyperplasia | Benign Prostatic HypertrophyCanada
-
Vantia LtdCompletedNocturia | Benign Prostatic Hypertrophy (BPH)Germany
-
IRCCS Policlinico S. MatteoCompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy With Outflow ObstructionItaly
-
American Medical SystemsCompletedBenign Prostatic Hyperplasia | BPH | Benign Prostatic Hypertrophy | Prostate Disease
Clinical Trials on Bead Block
-
University of BirminghamUnknownMalocclusion, Angle Class IIUnited Kingdom
-
Memorial Sloan Kettering Cancer CenterColumbia UniversityCompletedHepatocellular Carcinoma | Liver Cancer | HepatomaUnited States
-
University of California, San FranciscoTerminatedHepatocellular Carcinoma | ChemoembolizationUnited States
-
University Hospital Southampton NHS Foundation...BTG International Inc.UnknownBenign Prostatic HyperplasiaUnited Kingdom
-
Boston Scientific CorporationBiocompatibles UK LtdCompletedMetastatic Colorectal CancerUnited Kingdom, Austria, France
-
National Institutes of Health Clinical Center (CC)CompletedLiver Neoplasms | Liver Cancer | Hepatocellular Cancer | Hepatic CancerUnited States
-
Massachusetts General HospitalWithdrawnOsteoarthritis of Hip | Failure of Primary THAUnited States
-
Midwest Orthopaedics at RushUnknownTotal Hip Arthroplasty | Acetabular CupUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Maryland Cigarette Restitution FundWithdrawnObesity, Morbid | Prostate AdenocarcinomaUnited States
-
Anish GhodadraCompleted